Artios Pharma

The company's clients are primarily patients suffering from these hard-to-treat cancers. They operate in the biotechnology and pharmaceutical market, specifically in the cancer treatment sector. Their business model revolves around the research, development, and commercialization of DDR-targeting therapies. They generate revenue through the sale of these therapies and through partnerships with major pharmaceutical companies.

Artios' team, led by scientific founders Niall Martin, PhD, and Graeme Smith, PhD, are recognized as pioneers in DDR drug discovery. They have a robust pipeline and platform for DDR-based therapeutic opportunities, which includes the development of inhibitors with monotherapy potential, overcoming resistance to existing DDR-targeted therapies, and expanding the reach of the immune response.

One of their promising developments is ART0380, an orally dosed inhibitor that targets the ataxia telangiectasia and Rad3-related protein (ATR). This inhibitor can potentially induce DNA damage in sensitive cancer tissue while preserving DNA integrity in healthy tissue. ART0380 is being developed as an oral anticancer agent, both as a standalone treatment and in combination with other agents that cause DNA damage or suppress a cancer cell’s ability to repair DNA damage.